key: cord-0961219-lppfvfu1
authors: Croxford, Sara; Emanuel, Eva; Ibitoye, Ayeshat; Njoroge, Jacquelyn; Edmundson, Claire; Bardsley, Megan; Heinsbroek, Ellen; Hope, Vivian; Phipps, Emily
title: Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services
date: 2021-01-15
journal: Public Health
DOI: 10.1016/j.puhe.2021.01.004
sha: 9cdc6308efe236a7a5188c26f8236bc924d35a4f
doc_id: 961219
cord_uid: lppfvfu1

Objective To describe the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on people who inject drugs (PWID) in England, Wales and Northern Ireland. Study design Cross-sectional unlinked anonymous monitoring (UAM) Survey of PWID. Methods People who had ever injected psychoactive drugs were recruited to the UAM Survey by specialist drug/alcohol services in England, Wales and Northern Ireland. From June 2020, in addition to providing a dried blood spot sample and completing the UAM behavioural questionnaire, participants were asked to complete an enhanced coronavirus disease (COVID-19) questionnaire. Preliminary data are presented to the end of October and were compared to data from the 2019 UAM Survey, where possible. Results Between June and October, 288 PWID were recruited from England and Northern Ireland. One in nine (11%; 29/260) PWID reported testing positive for SARS-CoV-2 or experiencing COVID-19 symptoms. Fifteen percent (26/169) reported injecting more frequently in 2020 compared to 2019; cocaine injection in the preceding four weeks increased from 17% (242/1,456) to 25% (33/130). One in five PWID (22%; 35/188) reported difficulties in accessing HIV and hepatitis testing and one in four (26%; 47/179) reported difficulties in accessing equipment for safer injecting. Conclusions Our preliminary findings suggest that PWID have experienced negative impacts on health, behaviours and access to essential harm reduction, testing and treatment services due to the COVID-19 pandemic. Continued monitoring through surveillance and research is needed to understand the subsequent impact of COVID-19 on blood-borne virus transmission in this population and on health inequalities.

People who inject drugs (PWID) are potentially more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease (COVID-19) than other groups, due to a high prevalence of underlying health conditions and lifestyle risk factors [1] [2] [3] [4] . However, research on the extent to which PWID have been affected by the pandemic is limited thus far.

In June 2020, the Unlinked Anonymous Monitoring (UAM) Survey of PWID in England, Wales and Northern Ireland introduced an enhanced questionnaire to understand the impact of the COVID-19 pandemic. The UAM Survey is an annual cross-sectional survey that has been running across England and Wales since 1990 and Northern Ireland since 2002.

Methods of the survey have been described elsewhere 5 ; briefly, people who have ever injected psychoactive drugs are recruited through specialist drug agencies to self-complete an anonymous, unlinked demographic and behavioural questionnaire and provide a dried blood spot sample for HIV, hepatitis B and hepatitis C (HCV) testing. The survey has ethical approval from Public Health England and the London Research Ethics Committee (98/2/051).

We describe preliminary data, collected between June and October 2020, on the burden of COVID-19, changes in risk behaviours and access to services among PWID. We also compare PWID recruited to the UAM Survey in 2020 who completed the enhanced COVID-19 questionnaire to PWID recruited in 2019. Pearson chi-squared tests were used to compare differences in proportions (statistical significance p<0.05). Analyses were conducted using Stata v15 (StataCorp, College Station, US). In general, the demographic profile of the 288 people completing the enhanced questionnaire in 2020 was broadly similar to that of the people participating in the UAM Survey in 2019, in terms of median age at recruitment and region of birth (Table 1) . A higher proportion of 2020 participants were men (78% vs. 71%; p=0.015) and reported homelessness in the last year (61% vs. 42%; p<0.001). Of those homeless in 2020, 51% J o u r n a l P r e -p r o o f (75/147) reported being provided with accommodation at either a hotel, hostel, or council/housing association property through the pandemic response.

Overall, 22% (62/279) of respondents completing the enhanced questionnaire reported being tested for SARS-CoV-2 in 2020, with 2% (1/52) testing positive, 94% (49) testing negative and 4% (2) awaiting their test result at the time of questionnaire completion.

There were 29 people (11%) that reported developing a high temperature or a new continuous cough, common symptoms of COVID-19, at any point in 2020. A third (32%; 9/28) of this group reported attending hospital for these symptoms; of those attending hospital, 88% (7/8) went to A&E and 58% (4/7) were admitted. Of those admitted, half (50%; 2/4) were placed in intensive care (7% (2/28) of those attending hospital).

The majority of PWID completing the enhanced questionnaire reported their frequency of drug injection had remained the same or reduced (85%; 143/169) in 2020 compared to 2019, with only 15% (26) injecting more frequently. Over a quarter reported smoking drugs more frequently (27%; 64/237). However, 23% (50/213) of participants reported their primary drug or drug combination had changed. Compared to UAM Survey respondents in 2019, people participating in 2020 completing the COVID-19 questionnaire reported higher levels of cocaine (25% vs. 17%; p=0.011) and amphetamine (17% vs. 11%; p=0.034) injection in the last month (Table 1) ; the increase in amphetamine injection was not significant when comparing to 2019 participants recruited from the same centres. Higher levels of noninjecting use of cocaine (30% vs. 21%; p<0.001), amphetamines (14% vs. 7.0%; p<0.001), methamphetamine (3.6% vs. 1.3%; p=0.003) and pregabalin (28% vs. 19%; p<0.001) were also noted ( Table 1) . Direct sharing of needles, syringes and other injecting paraphernalia among participants who had injected during the last month increased slightly across years (46% vs. 37%; p=0.038) ( Table 1) ; however, this increase was not significant when comparing to 2019 participants recruited from the same centres. Overall, a quarter of respondents (25%; 43/174) reported drinking alcohol more frequently.

Over a third (35%; 77/220) of participants completing the enhanced questionnaire reported that drug/alcohol services were more difficult to access in 2020 than in 2019, with one in five 

Our findings demonstrate that PWID in England and Northern Ireland are at risk of SARS-CoV-2 infection and hospitalisation due to COVID-19. One in nine UAM Survey participants reported testing positive or experiencing COVID-19 symptoms. This is similar to estimates among people who use drugs from Norway; 13% of the 226 survey respondents reported currently experiencing COVID-19 symptoms (fever/change in taste/smell) in May/June and 12% reported a cough 6 . However, both these estimates of the burden of infection are based on self-reported data. Validation is currently underway to explore the potential for testing UAM Survey dried blood samples for SARS-CoV-2 antibodies to quantify seroprevalence among PWID.

These data also indicate that over the course of the pandemic there has been a shift in patterns of psychoactive drug use alongside a reduction in access to services for PWID, such as BBV testing and injecting equipment. This is consistent with reports of increased cocaine injecting and amphetamine use in regions of England, as well as increased use of, and harm linked to, benzodiazepines and pregabalin 7, 8 . The fact that there has been a disruption to services for PWID across England, Wales and Northern Ireland has also been well-documented 7, 9, 10 . In the North West of England, needle and syringe programme (NSP) coverage was found to have halved between March and April 9 . Continued monitoring is needed to understand the full and potentially lasting impact of these changes in drug use and reduced access to harm reduction on injection practices and BBV transmission, as well as on national HIV/HCV elimination efforts.

To the best of our knowledge, this is the largest study describing the burden of COVID-19 among PWID and the impact on access to health and harm reduction services. However, our study has a number of limitations. These data are preliminary and analyses only include enhanced questionnaires collected between June and October; some geographical regions were not represented. Given the limited sample size, we were not able to carry out further J o u r n a l P r e -p r o o f analysis to determine predictors of infection or service access. However, data from the COVID-19 questionnaire will continue to be collected in 2021, allowing for more in-depth analysis in future. 

Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks

EMCDDA update on the implications of COVID-19 for people who use drugs (PWUD) and drug service providers

Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs

Mitigating and learning from the impact of COVID-19 infection on addictive disorders

Unlinked Anonymous Monitoring (UAM) Survey of HIV and viral hepatitis among PWID: 2020 report

COVID-19 survey among people who use drugs in three cities in Norway

Shooting Up: Infections among people who inject drugs in the UK, 2019 -an update

Coronavirus triggers UK shortage of illicit drugs. The Guardian

Department of Health and Social Care, Public Health England. COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol

The authors would like to recognise the continued support of the specialist drug, alcohol and outreach services participating in the UAM Survey of PWID across England, Wales and Northern Ireland.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors have no competing interests to declare.

The UAM Survey of PWID has ethical approval from Public Health England and the London